A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors

Immune-checkpoint inhibitors (ICIs) including Programmed Death-1 (PD-1) or Programmed Death Ligand-1 (PD-L1) inhibitors determined a significant improvement in the treatment of several cancer types [1,2]. However, a considerable proportion of patients does not benefit from them [3,4]. Combining PD-1 or PD-L1 inhibitors with other therapeutic partners - including a second immunotherapeutic agent, targeted agents, chemotherapy or radiotherapy - has been increasingly pursued over the last years [5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research